AnaptysBio Shares Rise on FDA Approval of Jemperli as First Immunotherapy for MSI-H/dMMR Rectal Cancer
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
AnaptysBio climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain.
GSK subsidiary Tesaro and AnaptysBio file dueling lawsuits in Delaware court over alleged breaches of their 2014 Jemperli licensing agreement, with trial set for July 2026.
Rosnilimab UC trial discontinued after failing efficacy endpoint. AnaptysBio advances RA program & ANB033 (CeD). Plans firm for 2026 corporate split.
AnaptysBio announced plans to separate its business into 'Royalty Management Co' and 'Biopharma Co' by late 2026, aiming to unlock the potential value of its immunology pipeline and royalty assets.